Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 2;25(1):12.
doi: 10.1186/s13063-023-07880-2.

A randomised clinical trial study assessing the efficacy of 5% losartan potassium loaded in ethosomal gel to treat human keloids: a trial protocol

Yuni Eka Anggraini  1   2 , Niken Trisnowati  2 , Ronny Martien  3 , Retno Danarti  4
Affiliations

A randomised clinical trial study assessing the efficacy of 5% losartan potassium loaded in ethosomal gel to treat human keloids: a trial protocol

Yuni Eka Anggraini et al. Trials. .

Abstract

Background: Keloid is a skin disorder that results from excessive fibrous tissue growth in the area of the initial trauma. Treating keloids can be challenging since the success of various treatments varies from one study to another. Triamcinolone acetonide injection, a standard treatment, can cause undesirable side effects. Meanwhile, the effectiveness of existing topical therapies for keloids is not always reliable. The pro-inflammatory, pro-proliferative, and pro-fibrotic effects of angiotensin II in human skin contribute to keloid formation. Losartan potassium, an angiotensin II blocker, has the potential to act as an anti-keloid agent. Due to the thicker skin structure of a keloid and ease of application, ethosome gel is chosen as a safe and comfortable carrier for losartan potassium, making it a good choice for treating keloids.

Methods: In this randomised clinical trial, 46 adults with keloids were divided into two treatment groups. One group of 23 participants received 5% losartan potassium loaded in ethosomal gel, while the other group of 23 participants received intralesional injections of 10% triamcinolone acetonide. Over 12 weeks, changes in POSAS 3.0 scores, degree of erythema and pigmentation, surface area, thickness, and pliability of the keloids will be measured at four different times: baseline, 4 weeks, 8 weeks, and 12 weeks. Statistical analysis will be conducted using SPSS software version 24, with a significance level of p < 0.05.

Discussion: Losartan potassium is believed to be beneficial for keloid management because it inhibits the angiotensin II receptor, which plays a role in inflammation, proliferation, and fibrosis. This study examines the efficacy of 5% losartan potassium loaded in ethosomal gel for human keloids.

Trial registration: Clinicaltrial.gov identifier NCT05893108 . Registered on 7 June 2023.

Keywords: Angiotensin II; Angiotensin II receptor blocker; Efficacy; Losartan potassium; Randomised clinical trial; Triamcinolone acetonide.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Schedule of enrolment, interventions, and assessments
See this image and copyright information in PMC

References

    1. Dinulos JGH. Habif’s Clinical Dermatology. 7. Elsevier Inc.; 2021. Keloid and hypertrophic scars; pp. 799–801.
    1. Bock O, Schmid-Ott G, Malewski P, Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res. 2006;297(10):433–438. doi: 10.1007/s00403-006-0651-7. - DOI - PubMed
    1. Zhang X, Liu Y, Deng X, Deng C, Pan Y, Hu A. The correlation between quality of life and acceptability of disability in patients with facial burn scars. Front Bioeng Biotechnol. 2019;7:1–7. doi: 10.3389/fbioe.2019.00329. - DOI - PMC - PubMed
    1. Elsaie ML. Update on management of keloid and hypertrophic scars: a systemic review. J Cosmet Dermatol. 2021;20(9):2729–2738. doi: 10.1111/jocd.14310. - DOI - PubMed
    1. Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg. 2017;43:S3–18. doi: 10.1097/DSS.0000000000000819. - DOI - PubMed

Publication types

Associated data